Vendor Intelligence Report: Zhuoyue Biotechnology

Published 3 Jul 2026. 22-page investigative report on who is behind Zhuoyue Biotechnology: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 28 Finnrick lab tests, Zhuoyue Biotechnology has a 71% overall pass rate (20 pass / 7 fail). The average hides a split catalog: GHK-Cu is the strongest small-sample bright spot, Retatrutide is the more defensible GLP-1 line, and Tirzepatide is the clear problem product. The Tirzepatide record includes a vial with no Tirzepatide and severe overdose outliers; the full report shows how ratings shift under stricter grading.

The paper trail does not offset those lab concerns. The consumer storefront is tied at high confidence to a Wyoming LLC at a registered-agent address, while the China-side company reference remains a medium-confidence registry signal. Domain ownership is privacy-protected, there is no Wayback history, and the WhatsApp number also appears in a separate gray-market luxury-goods channel.

The most serious documentation issue is the vendor’s COA system. Zhuo Yue Labs markets products as HPLC-verified, third-party analyzed, and lot-traceable, yet the reviewed COAs are self-issued, name no independent lab, omit chromatograms, and carry regulatory/patent language investigators could not substantiate. The buyer read is directional rather than blanket: GHK-Cu looks comparatively strongest, Retatrutide requires caution and independent batch testing, and Tirzepatide should be treated as high concern.

Promotion risk is concentrated rather than noisy: no X or coupon-site network surfaced, but creator commissions/free vials and an operator-linked TikTok discount code make social proof a weak safety signal.

Inside the full report:

  • Appendix A with product-level Finnrick pass/fail data, rating trajectories, and methodology-divergence charts for all 3 tested products
  • COA archive teardown comparing self-issued documents against third-party-lab requirements
  • Corporate and infrastructure trail covering the Wyoming LLC, D&B China record, RDAP, DNS, and archive dead ends
  • TikTok and WhatsApp mapping linking the storefront, Locke Trades branding, and a separate gray-market seller contact
  • Affiliate, Reddit, and community-sentiment sweep with confidence levels and gaps
  • Open leads for beneficial ownership, China registry work, and shared-supplier boilerplate

Risk assessment

  • Tirzepatide quality-control risk — high: Tirzepatide shows 13 tests, 7 pass / 6 fail, 65.6%; field detail includes a no-active-ingredient vial and severe overdoses up to 119.8%.
  • Retatrutide quality-control risk — medium: Retatrutide is stronger at 10 tests, 9 pass / 1 fail, 84.23%, but field detail includes an 88.42% purity sample, underdosing up to 21%, and no batch traceability.
  • COA and traceability integrity risk — high: Vendor COAs are self-issued, name no third-party lab, omit chromatograms, cite unsupported Court Order No. 957195722§, and do not map vials to batch IDs.
  • Operator-transparency risk — high: Storefront uses Locke Trades LLC at a Wyoming registered-agent address, privacy-protected WHOIS, and a WhatsApp number also seen in Calla Vendor grey-market luxury-goods content.
  • Misleading credibility-claim risk — medium: Claims of third-party analysis, HPLC verification, lot traceability, and 150+ research initiatives are unsupported or misattribute public literature.
  • Affiliate-promotion risk — medium: Zhuoyue recruits creators with up to 20% commissions/free vials and @locketrades promotes code RT5FREE; disclosures were not visible in captured materials.